Drugs / S-Gboxin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06806228 | May 2026 → Oct 2027 | diffuse midline glioma, H3 K27M-mutant, giant cell glioblastoma, gliosarcoma | Petrov, Andrey | Suspended | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06439849 | — | diffuse midline glioma, H3 K27M-mutant, glioblastoma | Petrov, Andrey | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-Gboxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06806228 ↗ |
| Action | Inhibit | “it inhibits F 0 F 1 ATP synthase activity in tumor cells.” NCT06806228 ↗ |
| Route | Other | “the patient will receive a sublingual form of the lyophilized form of S-Gboxin at a dose of 10 mg/kg” NCT06439849 ↗ |